Back to News
Market Impact: 0.25
Xenix Medical Announces FDA Clearance of the Riva® Anchor Spinopelvic Fixation System with NanoACTIV™ Surface Technology
Source: Business Wire
Healthcare & BiotechProduct LaunchesRegulation & LegislationTechnology & Innovation
Xenix Medical announced FDA clearance for its Riva Anchor Spinopelvic Fixation System featuring NanoACTIV Surface Technology. The clearance enables commercialization of the spinal fixation system in the U.S. and is a positive regulatory milestone for the company, though the release provides no financial projections or sales estimates.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.60
More News
- How the US midterm elections reflected resistance to data centres
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI Party isn't Ending Because Of The Blue Wave Says Ives
- OpenAI to press ahead with data-center expansion despite midterm sweep, CFO tells CNBC
- SoftBank, ABB consider China carve-out to rescue $5.4bn robotics deal
- A ‘geologic freak’ called the Smackover may end America’s lithium dependence on China, and Big Oil is already there